Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;104(1):407-420.
doi: 10.1007/s00277-024-06144-6. Epub 2025 Jan 8.

The association between NADPH oxidase (NOX) polymorphisms with immunohistochemistry and survival in diffuse large B cell lymphoma patients

Chao Chen #  1   2 , Quan Dong #  3 , Huiqi Wang #  3 , Shiqi Dong  3 , Shufan Wang  3 , Wenxin Lin  3 , Chuiming Jia  4 , Mei Dong  3 , Yan Jin #  5   6   7 , Duo Liu #  8
Affiliations

The association between NADPH oxidase (NOX) polymorphisms with immunohistochemistry and survival in diffuse large B cell lymphoma patients

Chao Chen et al. Ann Hematol. 2025 Jan.

Abstract

The purpose of this study was to comprehensively analyze the prediction role of NADPH oxidase (NOX)-related polymorphisms (NCF4: rs1883112, CYBA: rs4673, RAC2: rs13058338) and immunohistochemical indices on survival in diffuse large B-cell lymphoma (DLBCL).The impact of NOX polymorphisms were evaluated in 335 DLBCL patients treated with R (rituximab)-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) from Harbin Medical University Cancer Hospital. We also collected information on their immunohistochemical expression and clinical outcomes.Among the patients treated with R-CHOP therapy, the patients with CyclinD1 (+) had significantly shorter progression-free survival (PFS) (p = 0.001) and event-free survival (EFS) (p < 0.001) than CyclinD1 (-) patients. Among patients received CHOP therapy, PFS was significantly longer in CD20 (+) patients (p = 0.011) than in CD20(-) patients. Among the patients treated with R-CHOP therapy, the PFS (p = 0.020) and EFS (p < 0.001) of patients with NCF4 rs1883112 AA/AG genotype were significantly longer than the patients with GG genotype. Patients treated with R-CHOP therapy and with RAC2 rs13058338 AA/AT genotype were more likely to have grade III or higher myelosuppression compared to patients with TT genotype (p = 0.027). Patients treated with CHOP therapy and with RAC2 rs13058338 AA/AT genotype were more likely to have grade III or higher systemic adverse events (p = 0.029). Cox regression analysis showed that NCF4 rs1883112 GG genotype and CyclinD1 (+) were the factors contributing to the poor outcomes in DLBCL patients treated with R-CHOP therapy.In conclusion, the results suggested that the NCF4 rs1883112 G allele may be a poor prognostic biomarker, especially for the DLBCL patients with CD3(-), CD5 (-), CD10 (-), Bcl-2 (+), Bcl-6 (+) or Ki-67(%) < 80%.

Keywords: DLBCL; Immunohistochemistry; NADPH oxidase; Polymorphisms; Survival rate.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (Ethics Committee of Harbin Medical University (HMUIRB20160004)) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study. Competing interests: The authors declare no competing interests.

References

    1. Novaković RS, Iztok SG et al (2016) The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients. Oncol Lett 11:3332–3336 - PubMed - PMC
    1. Lodhi Niraj T, Moe N, Poonam et al (2020) Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine. Oncotarget 11:4045–4073 - PubMed - PMC
    1. Huang H, Li Z, Huang C et al (2018) CD5 and CD43 expression are associate with poor prognosis in DLBCL patients. Open Med 13:605–609
    1. NCCN clinical practice guidelines in oncology (NCCN guidelines) B cell lymphoma (version 2020.04) Available from URL: https://nccn.org
    1. Shoko M, Noriko N, Norihito I, Hirofumi Y, Naoko T, Kengo T, Yuko M et al (2021) Impact of omission/reduction of vincristine from R-CHOP in treatment of DLBCL. J Cli lymphoma, myeloma leukemia 21(3):162–169

MeSH terms

LinkOut - more resources